AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
AstraZeneca AZN stock has declined 6.4% in the past three months.
Although AstraZeneca faces its share of challenges, a significant portion of this price decline is attributed to broader market uncertainties and a volatile macroeconomic environment.
The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries hurt global stock markets. Though the massive tariffs imposed by the United States and China are now on a pause, it is only a temporary suspension, and no one knows what will happen after the 90-day tariff suspension ends. The uncertainty around tariffs and trade production measures remains, slowing down economic growth.
Although pharmaceuticals have been exempted from tariffs in the first round, they could be Trump's target in the next round, considering the President's goal to shift pharmaceutical production back to the United States, primarily from European and Asian countries.
Trump and the Republican government also continue to stress on the control of drug prices with the latest attempt being his 'most favored nations' policy.'
Let's understand AZN's strengths and weaknesses to better analyze how to play the stock in an uncertain macro environment.
AZN's Strong Portfolio of Blockbuster Drugs
AstraZeneca boasts a diversified geographical footprint as well as a product portfolio with several blockbuster medicines. AstraZeneca now has 16 blockbuster medicines in its portfolio with sales exceeding $1 billion, including Tagrisso, Fasenra, Farxiga, Imfinzi, Lynparza (partnered with Merck [
MRK
]), Calquence and Ultomiris. These drugs are driving the company's top line, backed by increasing demand trends. The company is confident that the growth will continue in 2025. Almost every new product it has launched in recent years has done well.
Newer drugs like Wainua, Airsupra, Saphnelo, Datroway (partnered with Daiichi Sankyo) and Truqap are also expected to continue to contribute to top-line growth in 2025.
AZN Enjoys Strong Position in the Oncology Space
Oncology is AstraZeneca's biggest segment. The company is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates. Oncology sales (comprising around 41% of AstraZeneca's total revenues) rose 13% in the first quarter of 2025, generating $5.6 billion in sales. The strong oncology performance is being driven by medicines such as Tagrisso, Merck-partnered Lynparza, Imfinzi, Calquence and Daiichi Sankyo-partnered Enhertu.
A key new cancer drug approval was that of Truqap for HR-positive, HER2-negative (HR+ HER2-) breast cancer. The drug has seen a robust launch, recording sales of $430 million in 2024 and $132 million in the first quarter of 2025. In January this year, AstraZeneca and partner Daiichi's drug, Datroway, was approved by the FDA for HR+ HER2- breast cancer, while a regulatory application is under review for EGFR-mutated non-small cell lung cancer (NSCLC). Datroway witnessed encouraging early launch signals in the United States.
AstraZeneca expects continued growth of its oncology medicines in 2025, particularly Tagrisso, Enhertu and Imfinzi, despite the incremental impact of the Part D redesign.
Several Headwinds to Hurt AZN's Top Line in 2025
The impact of Part D redesign hurt sales of AZN's older drugs, Tagrisso, Lynparza and Ultomiris, as well as newer drugs, Truqap and Wainua, in the United States in the first quarter of 2025, with the trend expected to continue through the rest of the year.
AstraZeneca expects Farxiga and Lynparza to be included in the volume-based procurement plans in China in mid-2025, which can hurt sales of these drugs in the country.
Pricing and competitive pressure in Europe and generic competition in some emerging markets are expected to hurt sales of some drugs. Brilinta generics are expected to be launched in the United States in 2025. This will hurt sales of the drug. Biosimilar versions of Soliris were launched in the United States in March 2025, which, along with successful conversion to Ultomiris, biosimilar pressure in Europe and unfavorable order timing in certain tender markets, is expected to lead to a continuous decline in sales of Soliris.
AstraZeneca is facing ongoing investigations at its China subsidiary. The Chinese authorities are investigating some current and former AstraZeneca employees at its China subsidiary for medical insurance fraud, illegal drug importation and personal information breaches.
AZN Stock's Price, Valuation & Estimates
AZN stock has risen 8.2% so far this year againsta decrease of 3.1% for the industry. The stock has also outperformed the sector and S&P 500 index, as seen in the chart below.
AZN Stock Outperforms Industry, Sector & S&P 500
From a valuation standpoint, AstraZeneca is slightly expensive. Going by the price/earnings ratio, the company's shares currently trade at 14.93 forward earnings, slightly higher than 14.74 for the industry. However, AZN's stock is trading below its 5-year mean of 18.05. The stock is also much cheaper than other large drugmakers like Eli Lilly LLY and Novo Nordisk NVO. Eli Lilly and Novo Nordisk currently dominate the obesity space.
AZN Stock Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has risen from $4.47 per share to $4.50 per share over the past 60 days. For 2026, earnings estimates have risen from $4.95 per share to $4.98 per share over the same timeframe.
AZN Estimate Movement
Consider Buying AZN Stock
Despite the potential impact from Part D redesign, AstraZeneca expects total revenues to grow by a high single-digit percentage at CER in 2025. Growth momentum in Oncology and CVRM(cardiovascular, renal and metabolism) segments is expected to continue in 2025. However, in Rare Disease, though AstraZeneca expects growth in 2025, it will be at a slower pace than in 2024.
Regarding the potential impact of tariffs, AstraZeneca had a positive tone on the first-quarter conference call. The company said it has limited commercialized finished medicines imported to the United States from China, which lowers its exposure to potential China tariffs on pharmaceuticals. It also has a substantial and growing manufacturing footprint in the United States, and the majority of its medicines sold in the United States are manufactured domestically.
It does import some medicines from Europe but believes that if tariffs on pharmaceutical imports from Europe are implemented in a similar range as other industries, it will be manageable and allow the company to remain within its guidance range for EPS. In 2025, AstraZeneca expects core EPS to increase by a low double-digit percentage.
Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. AstraZeneca expects to generate$80 billion in total revenues by 2030, a significant increase from the $54 billion it generated in 2024. By the said time frame, AstraZeneca plans to launch 20 new medicines, with nine new medicines already launched/approved. It believes that many of these new medicines will have the potential to generate more than $5 billion in peak-year revenues.
The company is also on track to achieve a mid-30s percentage core operating margin by 2026
Considering AZN's growth prospects, investors may take advantage of the recent dip and consider buying this Zacks Rank #2 (Buy) stock, more so as it is trading below its five-year mean. Consistently rising estimates also indicate analysts' optimistic outlook for growth. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Novo Nordisk A/S (NVO): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
If I Could Only Buy and Hold a Single Stock, This Would Be It.
Let's make this clear from the start: I would never recommend owning just one stock for the long haul. A proper nest egg needs some variety, either in a carefully assembled basket of diverse stocks or focused on a broad market-tracking exchange-traded fund (ETF). For the sake of argument, however, I could imagine buying some Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) stock and just letting it roll. The usual suspects aren't diverse enough for this challenge I know, I know. You wanted me to double down on Amazon (NASDAQ: AMZN), whose stock has absolutely crushed the general market in the long run. Or I could have picked Netflix (NASDAQ: NFLX), the media-streaming pioneer that's created most of my wealth so far and that might join the trillion-dollar market cap club in a few years. Perhaps you expected Nvidia (NASDAQ: NVDA), with its unmatched five-year returns and huge long-term future in the artificial intelligence (AI) industry. These stocks sure tick a few of the right boxes, but none of them are as naturally diversified as Berkshire Hathaway. That's really what I'm looking for in a "single stock for all ages." Why my biggest winners don't make the cut I own all three of the suggested Berkshire alternatives above, by the way. Netflix Netflix was an early name in my portfolio, inspired by fellow Fool Rick Munarriz's in-depth analysis of the company in the mid-2000s. When Netflix went through the Qwikster-branded separation of DVD and streaming services, I doubled down on my investment at a fantastic price. That particular Netflix stake has gained 10,350% in less than 14 years. But that's just my favorite play on the future of digital media services. I would never dare to make Netflix my only holding, just in case somebody builds a better media-streaming mousetrap. Amazon I wish I had pounced on Amazon much earlier, like Motley Fool co-founders Tom and David Gardner did. But I dragged my feet, and watched the online bookstore become an e-commerce buffet with a highly profitable side of cloud computing services. My oldest Amazon investment is only up by 430% since January 2017. Still, Amazon only operates in a couple of business sectors. The company (and stock) could be vulnerable to a sudden sea change in cloud computing, possibly led by Microsoft 's (NASDAQ: MSFT) Windows Azure. And how well would Amazon's dominant e-commerce business perform if global rivals such as Alibaba (NYSE: BABA) or MercadoLibre (NASDAQ: MELI) found some traction in the American market? Amazon is not a one-trick pony, but the company should pick up a few more skills before entering this single-stock discussion. Nvidia I'm especially worried about Nvidia's long-term tenacity. The early leader in AI accelerator hardware could very well run into a superior alternative in the next few years. The risk only grows larger if you stretch the timeline out over decades. Rivals like Advanced Micro Devices (NASDAQ: AMD) and Intel (NASDAQ: INTC) control tiny slices of the AI chip opportunity so far, but that could change. The next market-defining AI winner could be some upstart I haven't heard of yet. Moreover, leading cloud computing experts such as Microsoft and Amazon already design AI accelerators of their own, hoping to meet their exact needs at a lower cost. Nvidia's big growth spurt might have a few years left in it. I'm just not convinced that the stock will continue to rise after that. My largest Nvidia purchase has posted a 780% gain since June 2022, but I cashed in on those paper gains and sold most of my Nvidia shares earlier this year. This pony needs to learn a few more tricks, too. Berkshire is the Swiss Army knife of stocks So diversity sets Berkshire apart from the biggest success stories of this era. Sure, Warren Buffett's stock-picking and wealth management expertise deserves tons of respect. But he is also known as a great mentor, and many of Berkshire's top-performing picks in recent years were added by Buffett's lieutenants. I expect the company to continue doing well when the Oracle of Omaha retires at the end of 2025. The stock is kind of like a carefully curated ETF. Berkshire Hathaway owns and operates 68 distinct companies these days. The names range from GEICO car insurance and Duracell batteries to Business Wire information services and the Burlington Northern Santa Fe railroad. Berkshire dabbles in e-commerce (Oriental Trading Company) and clothing (Fruit of the Loom), not to mention home construction (Clayton Homes) and fast food (Dairy Queen). This business list is almost as diverse as the S&P 500 (SNPINDEX: ^GSPC) market index. And that's just Berkshire's in-house brands. The company also owns stock in about 40 public companies. The largest investments include a $60.7 billion stake in Apple (NASDAQ: AAPL), a $45.1 billion position in American Express (NYSE: AXP), and a $28.5 billion holding of Coca-Cola (NYSE: KO). That's consumer electronics, financial services, and beverage distribution. Apple's gigantic presence may look risky, but the danger looks smaller when you also consider Berkshire's epic collection of fully owned businesses. Do you see a theme here? I do, but it's not a single industry. Berkshire is all about diversity, shielding the company and its investors against the temporary ups and downs in any one particular industry. Full disclosure: I don't own Berkshire (yet) I don't actually own any Berkshire Hathaway stock yet. I get my portfolio diversification kicks in other ways, with several dozen hand-picked stocks and a couple of broad index funds serving this purpose. That's arguably a mistake, since Berkshire's stock tends to outperform the S&P 500 in the long run, and I can't compete with the Buffett team's stock-picking skill. So if you're starting a new portfolio today, or just looking for an alternative to the common S&P 500 index funds, you should give Berkshire Hathaway a serious look. It's definitely a safer long-term bet than Nvidia, Netflix, or even Amazon. Should you invest $1,000 in Berkshire Hathaway right now? Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. American Express is an advertising partner of Motley Fool Money. Anders Bylund has positions in Alibaba Group, Amazon, Intel, Netflix, and Nvidia. The Motley Fool has positions in and recommends Advanced Micro Devices, Amazon, Apple, Berkshire Hathaway, Intel, MercadoLibre, Microsoft, Netflix, and Nvidia. The Motley Fool recommends Alibaba Group and recommends the following options: long January 2026 $395 calls on Microsoft, short August 2025 $24 calls on Intel, and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Globe and Mail
2 hours ago
- Globe and Mail
‘There's Still Time to Invest in Snowflake Stock,' Says Five-Star Analyst
Although Snowflake (SNOW) shares have already climbed over 35% this year, UBS believes that the software stock still has more room to grow. Following Snowflake's annual Summit in San Francisco, UBS upgraded the stock from Neutral to Buy and raised its price target from $210 to $265. Despite being late to the upgrade, analysts led by five-star rated Karl Keirstead said that Snowflake's performance has only started improving in the last few quarters, and that the broader AI-related investment cycle is just beginning. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Indeed, UBS noted that Snowflake is one of the companies benefiting from the need for 'AI-ready' data, along with Palantir (PLTR) and Databricks. The analysts also pointed out that more software companies like Salesforce (CRM), ServiceNow (NOW), and SAP (SAP) are moving into the data space, which they see as evidence of the growing demand for data. As a result, UBS believes that Snowflake investors haven't fully priced in this growth potential yet and that there's still time to invest before the full AI boom happens. Separately, Morgan Stanley kept its Equal-weight rating and $200 price target despite Snowflake's strengths in data security, ease of use, and multi-cloud capabilities. While the analysts led by five-star rated Keith Weiss praised the company's role in secure AI integration, they remain cautious about the stock's high valuation, which sits at about 55 times the expected free cash flow for 2026. Nevertheless, it is worth mentioning that Snowflake's expansion into data engineering and AI has significantly increased its market opportunity and might justify its premium valuation. Is SNOW a Good Buy Right Now? Overall, analysts have a Strong Buy consensus rating on SNOW stock based on 34 Buys, six Holds, and zero Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average SNOW price target of $225.03 per share implies 6.4% upside potential. See more SNOW analyst ratings
CTV News
2 hours ago
- CTV News
Trump says Elon Musk could face ‘serious consequences' if he backs Democratic candidates
Tesla and SpaceX CEO Elon Musk, from left, Republican presidential nominee former President Donald Trump and Republican vice presidential nominee Sen. JD Vance, R-Ohio, attend a campaign event, Oct. 5, 2024, in Butler, Pa. (AP Photo/Alex Brandon, File) BRIDGEWATER, N.J. — U.S. President Donald Trump is not backing off his battle with Elon Musk, saying Saturday that he has no desire to repair their relationship and warning that his former ally and campaign benefactor could face 'serious consequences' if he tries to help Democrats in upcoming elections. Trump told NBC's Kristen Welker in a phone interview that he has no plans to make up with Musk. Asked specifically if he thought his relationship with the mega-billionaire CEO of Tesla and SpaceX is over, Trump responded, 'I would assume so, yeah.' 'I'm too busy doing other things,' Trump continued. 'You know, I won an election in a landslide. I gave him a lot of breaks, long before this happened, I gave him breaks in my first administration, and saved his life in my first administration, I have no intention of speaking to him.' The U.S. president also issued a warning amid chatter that Musk could back Democratic lawmakers and candidates in the 2026 midterm elections. 'If he does, he'll have to pay the consequences for that,' Trump told NBC, though he declined to share what those consequences would be. Musk's businesses have many lucrative federal contracts. The president's latest comments suggest Musk is moving from close ally to a potential new target for Trump, who has aggressively wielded the powers of his office to crack down on critics and punish perceived enemies. As a major government contractor, Musk's businesses could be particularly vulnerable to retribution. The dramatic rupture between the president and the world's richest man began Thursday, with Musk's public criticism of Trump's 'big beautiful bill' pending on Capitol Hill. Musk has warned that the bill will increase the federal deficit and called it a 'disgusting abomination.' Trump and Musk began trading bitterly personal attacks on social media, sending the White House and GOP congressional leaders scrambling to assess the fallout. U.S. Vice President JD Vance, in an interview Friday, tried to downplay the feud. He said Musk was making a 'huge mistake' going after Trump, but tried to downplay it as an 'emotional guy' getting frustrated. 'I hope that eventually Elon comes back into the fold. Maybe that's not possible now because he's gone so nuclear,' Vance said. Other Republicans in recent days urged the two men to mend fences. Musk's torrent of social media posts attacking Trump came as the president portrayed him as disgruntled and 'CRAZY' and threatened to cut the government contracts held by his businesses. Musk, who runs electric vehicle maker Tesla, internet company Starlink and rocket company SpaceX, lambasted Trump's centerpiece tax cuts and spending bill but also suggested Trump should be impeached and claimed without evidence that the government was concealing information about the president's association with infamous pedophile Jeffrey Epstein. 'Look, it happens to everybody,' Vance said in the interview. 'I've flown off the handle way worse than Elon Musk did in the last 24 hours.' Vance made the comments in an interview with " manosphere" comedian Theo Von, who last month joked about snorting drugs off a mixed-race baby and the sexuality of men in the U.S. Navy when he opened for Trump at a military base in Qatar. The vice president told Von that as Musk for days was calling on social media for Congress to kill Trump's 'Big Beautiful Bill,' the president was 'getting a little frustrated, feeling like some of the criticisms were unfair coming from Elon, but I think has been very restrained because the president doesn't think that he needs to be in a blood feud with Elon Musk.' 'I actually think if Elon chilled out a little bit, everything would be fine,' he added. Musk appeared by Saturday morning to have deleted his posts about Epstein. The interview was taped Thursday as Musk's posts were unfurling on X, the social media network the billionaire owns. During the interview, Von showed the vice president Musk's claim that Trump's administration hasn't released all the records related to Epstein because Trump is mentioned in them. Vance responded to that, saying, 'Absolutely not. Donald Trump didn't do anything wrong with Jeffrey Epstein.' 'This stuff is just not helpful,' Vance said in response to another post shared by Musk calling for Trump to be impeached and replaced with Vance. 'It's totally insane. The president is doing a good job.' Vance called Musk an 'incredible entrepreneur,' and said that Musk's Department of Government Efficiency, which sought to cut government spending and laid off or pushed out thousands of workers, was 'really good.' The vice president also defended the bill that has drawn Musk's ire, and said its central goal was not to cut spending but to extend the 2017 tax cuts approved in Trump's first term. The bill would slash spending but also leave some 10.9 million more people without health insurance and spike deficits by US$2.4 trillion over the decade, according to the nonpartisan Congressional Budget Office. 'It's a good bill,' Vance said. 'It's not a perfect bill.' He also said it was ridiculous for some House Republicans who voted for the bill but later found parts objectionable to claim they hadn't had time to read it. Vance said the text had been available for weeks and said, 'the idea that people haven't had an opportunity to actually read it is ridiculous.' Elsewhere in the interview, Vance laughed as Von cracked jokes about famed abolitionist Frederick Douglass' sexuality. 'We're gonna talk to the Smithsonian about putting up an exhibit on that,' Vance joked. 'And Theo Von, you can be the narrator for this new understanding of the history of Frederick Douglass.' The podcaster also asked the vice president if he 'got high' on election night to celebrate Trump's victory. Vance laughed and joked that he wouldn't admit it if he did. 'I did not get high,' he then said. 'I did have a fair amount to drink that night.' The interview was taped in Nashville at a restaurant owned by musician Kid Rock, a Trump ally. Article by Michelle L. Price and Bill Barrow.
